Medical Condition News

RSS

Improvements in trauma care could save two million lives

Up to two million lives, annually, could be saved globally with improvements in trauma care, particularly in low- and middle-income countries. This estimate by Charles Mock, from the University of Washington in Seattle, and his team provides support for investment in and greater attention to strengthening trauma care services globally. Their work is published online in Springer's World Journal of Surgery.

19 Mar 2012

Ampio completes partial planned interim review in Optina trial for diabetic macular edema

Ampio Pharmaceuticals, Inc., a biopharmaceutical company conducting clinical trials on its three lead drugs (Zertane completed two phase III studies, Ampion-completed proof of concept studies and Optina), licensing distribution of these drugs and engaged in further drug development, today announced that it completed the planned interim review of the first 50% of patients enrolled in the Optina trial for diabetic macular edema.

19 Mar 2012

DBS introduces novel Multiplex Immunohistochemistry cancer kits

Diagnostic Biosystems, a specialty Immunohistochemistry company, announces its debut as an automated IHC company, introducing the Mosaic 360 System with a product offering of novel Multiplex Immunohistochemistry kits and a complementary line of optimized IHC reagents.

19 Mar 2012

Biomedical Systems launches wireless ambulatory ECG monitoring system for management of AF

Biomedical Systems, a global provider of cardiac diagnostic services and products, has introduced the TruVue® Wireless Ambulatory ECG Monitoring System for the diagnosis and management of atrial fibrillation and other complex cardiac arrhythmia.

19 Mar 2012

Alnylam commences dosing in ALN-TTR02 Phase I clinical trial for TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis (ATTR). The study is aimed at evaluating the safety and tolerability of ALN-TTR02 in healthy volunteers.

19 Mar 2012

Study confirms value of Cambridge Heart's MTWA test for SCA

Cambridge Heart, Inc., a developer of non-invasive diagnostic tests for cardiac disease, today announced that a new study published on-line in the Heart Rhythm Journal confirms the value of Microvolt T-Wave Alternans (MTWA) testing for identifying patients at risk of sudden cardiac arrest.

19 Mar 2012

IOB, Delcath to launch CHEMOSAT system for Spanish cancer patients

Delcath Systems, Inc. announced today that the Company has entered into an initial launch and training agreement for the Delcath Hepatic CHEMOSAT Delivery system with the Instituto Oncologico Baselga (IOB), Grupo Quiron—a private hospital located in Barcelona, Spain.

19 Mar 2012

Top-line data from Provectus' PH-10 Phase 2 trial on plaque psoriasis

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced top-line data for the company's randomized controlled trial (RCT) of PH-10 for mild-to-moderate plaque psoriasis.

19 Mar 2012

Convergence initiates CNV1014802 Phase II study in trigeminal neuralgia

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines, today announced that the Phase II proof of concept study for CNV1014802 for the treatment of pain associated with trigeminal neuralgia (TN) has started.

19 Mar 2012

Different mechanisms might be involved in relapsing and progressive onset MS

Patients with relapsing onset Multiple Sclerosis (MS) who consumed alcohol, wine, coffee and fish on a regular basis took four to seven years longer to reach the point where they needed a walking aid than people who never consumed them. However the study, published in the April issue of the European Journal of Neurology, did not observe the same patterns in patients with progressive onset MS.

19 Mar 2012

New software tool can accurately estimate risk of heart disease

University of Granada researchers have developed a software tool that makes an accurate estimation of the risk that a person has to suffer a heart disease. In addition, this software tool allows the performance of massive risk estimations, i.e. it helps estimating the risk that a specific population group has of suffering a heart condition. The researchers employed a sample including 3 000 patients.

19 Mar 2012

EU-funded 'afresh'-project looks at food and physical activity

Food and physical activity are looked at together in the EU-funded "afresh"-project. Eight regional clusters - strong in food and/or health - currently are setting up their joint future agenda aiming at the prevention of diet-and activity related deseases like obesity, diabetes, cardiovasculaire deseases, osteoporose, etc.

19 Mar 2012

Air emissions near natural gas drilling sites may contribute to health problems

In a new study, researchers from the Colorado School of Public Health have shown that air pollution caused by hydraulic fracturing or fracking may contribute to acute and chronic health problems for those living near natural gas drilling sites.

19 Mar 2012

Researchers show how errant form of LYP can disrupt the immune system

Autoimmune diseases, such as Type I diabetes and rheumatoid arthritis, are caused by an immune system gone haywire, where the body's defense system assaults and destroys healthy tissues. A mutant form of a protein called LYP has been implicated in multiple autoimmune diseases, but the precise molecular pathway involved has been unknown.

19 Mar 2012

Addition of two MRI sequences to MRPA improves detection of pulmonary embolism

New research shows that the addition of two magnetic resonance imaging (MRI) sequences to a common MR angiography technique significantly improves detection of pulmonary embolism, a potentially life-threatening condition traditionally diagnosed through computed tomography.

19 Mar 2012

East Asian BIM gene variant contributes to drug resistance in cancer

A multi-national research team led by scientists at Duke-NUS Graduate Medical School has identified the reason why some patients fail to respond to some of the most successful cancer drugs.

19 Mar 2012

Study reveals how Bdnf gene mutation contributes to severe obesity

Researchers at Georgetown University Medical Center have revealed how a mutation in a single gene is responsible for the inability of neurons to effectively pass along appetite suppressing signals from the body to the right place in the brain. What results is obesity caused by a voracious appetite.

19 Mar 2012

Klf4 protein an important regulator of inflammation: HNK study

Microglia are the first line defence of the brain and are constantly looking for infections to fight off. Overactive microglia can cause uncontrolled inflammation within the brain, which can in turn lead to neuronal damage. New research published in BioMed Central's open access journal Journal of Neuroinflammation shows that, honokiol (HNK) is able to down-regulate the production of pro-inflammatory cytokines and inflammatory enzymes in activated microglia via Klf4, a protein known to regulate DNA.

19 Mar 2012

Scientist generates mutant version of IL-2 protein to treat advanced cancers

The utility of a naturally occurring protein given, sometimes to great effect, as a drug to treat advanced cancers is limited by the severe side effects it sometimes causes. But a Stanford University School of Medicine scientist has generated a mutant version of the protein whose modified shape renders it substantially more potent than the natural protein while reducing its toxicity.

19 Mar 2012

Westmead Hospital endorse a new medical device designed to increase blood circulation and prevent Deep Vein Thrombosis

A new medical device, the geko™, designed to increase blood circulation through neuromuscular electro–stimulation to the common peroneal nerve, has received the positive endorsement of Westmead Hospital, New South Wales, as an important new development in the prevention of Deep Vein Thrombosis (DVT).

18 Mar 2012